Nachrichten zur Alkermes plc Aktie

Alkermes (ALKS) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Alkermes (ALKS) closed at $19.99, marking a -0.05% move from the previous day....…

Alkermes (ALKS) Gains As Market Dips: What You Should Know

Alkermes (ALKS) closed the most recent trading day at $19.52, moving +1.61% from the previous trading session....…

Alkermes: It Takes More

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

FRA:Deletion of Instruments from XETRA - 23.12.2019-001

The following instruments on XETRA do have their last trading day on 23.12.2019 Die folgenden Instrumente in XETRA haben ihren letzten…

Alkermes (ALKS) Stock Sinks As Market Gains: What You Should Know

Alkermes (ALKS) closed the most recent trading day at $20.92, moving -0.66% from the previous trading session....…

All You Need to Know About Alkermes (ALKS) Rating Upgrade to Strong Buy

Alkermes (ALKS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the companys earnings prospects.…

The Zacks Analyst Blog Highlights: Baidu, Alkermes, Commvault Systems, Veoneer and Zuora

The Zacks Analyst Blog Highlights: Baidu, Alkermes, Commvault Systems, Veoneer and Zuora...…

FDA warns Alkermes over Vivitrol misbranding

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

UPDATE 1-FDA issues warning letter to Alkermes over opioid addiction treatment ad

A print advertisement of Alkermes Plcs addiction treatment, Vivitrol, is false or misleading as it omits important risk information associated with its…

FDA told Alkermes to stop publishing Vivitrol ad

Shares of Alkermes were down 2.74% after the Food and Drug Administration published a warning letter alleging Vivitrol ads…

FDA issues warning letter to Alkermes over opioid addiction treatment ad

A print advertisement of Alkermes Plcs addiction treatment, Vivitrol, is false or misleading as it omits important risk information associated with its…

Alkermes to Present at the Evercore ISI 2nd Annual HealthCONx Conference

DUBLIN , Nov. 26, 2019 /PRNewswire/ --  …

Why Is Alkermes Stock Down 30% So Far This Year-

Alkermes (NASDAQ: ALKS) is a biotech company based out of Ireland that manufactures novel (patented) drugs in central nervous system…

Alkermes completes acquisition of Rodin Therapeutics

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Alkermes Completes Acquisition of Rodin Therapeutics

DUBLIN , Nov. 25, 2019 /PRNewswire/ --  Alkermes plc  (Nasdaq:…

Alkermes plc (ALKS) Investor Presentation - Sliideshow

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Alkermes submits NDA for ALKS 3831 for schizophrenia and bipolar I disorder

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Alkermes Submits New Drug Application to U.S. Food and Drug Administration for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder

DUBLIN , Nov. 19, 2019 /PRNewswire/ --  Alkermes plc (Nasdaq:…

Alkermes to buy Rodin Therapeutics for up to $950m

As per the terms of the deal, Rodin’s security holders will secure an upfront cash payment of $100m upon completion…

Alkermes acquires Rodin Therapeutics for up to $950M

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Alkermes to acquire Rodin Therapeutics for up to $950 million

Alkermes Plc said Monday it has agreed to acquire the privately held biopharmaceutical company Rodin Therapeutics for an upfront cash…

Alkermes to Acquire Rodin Therapeutics

DUBLIN and BOSTON , Nov. 18, 2019 /PRNewswire/ -- …

Alkermes Announces Receipt of $150 Million Milestone Payment from Biogen Related to FDA Approval of VUMERITY

DUBLIN , Nov. 12, 2019 /PRNewswire/ --  Alkermes plc (Nasdaq:…

Biotech Stock On The Radar: Alkermes At A Crossroads

Alkermes Plc (NASDAQ: ALKS), an actively traded, mid-cap biotech, has lost about 32% year-to-date. Dublin, Ireland-based Alkermes is a global biopharma…

Zacks.com featured highlights include: Qualys, Fortinet, Zumiez, Commvault Systems and Alkermes

Zacks.com featured highlights include: Qualys, Fortinet, Zumiez, Commvault Systems and Alkermes...…

UPDATE 1-FDA approves Biogen and Alkermes multiple sclerosis drug

The U.S. Food and Drug Administration approved Biogen Inc and partner Alkermes Plcs oral drug to treat multiple sclerosis, the companies said…

FDA approves multiple sclerosis drug from Biogen and Alkermes

Biogen Inc and partner Alkermes Plc said on Wednesday that the U.S. Food and Drug Administration approved their oral drug to treat…

Biogens and Alkermes Vumerity gets FDA approval for MS; Biogens stock surges

Biogen Inc. and Alkermes PLC said Wednesday that U.S. Food and Drug Administration approved Vumerity for the treatment…

Alkermes plcs (ALKS) CEO Richard Pops on Q3 2019 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Alkermes PLC (ALKS) Q3 2019 Earnings Call Transcript

ALKS earnings call for the period ending September 30, 2019....…

Alkermes (ALKS) Reports Q3 Loss, Tops Revenue Estimates

Alkermes (ALKS) delivered earnings and revenue surprises of 80.00% and 1.00%, respectively, for the quarter ended September 2019. Do the…

Alkermes Plc Reports Third Quarter 2019 Financial Results and Implementation of Restructuring

DUBLIN , Oct. 23, 2019 /PRNewswire/ --  Alkermes plc  (Nasdaq:…

Alkermes teams up with Fred Hutchinson Cancer Research Center for immuno-oncology drug candidate

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Alkermes Announces Clinical Collaboration With Fred Hutchinson Cancer Research Center for Novel Immuno-Oncology Drug Candidate ALKS 4230

DUBLIN , Oct. 21, 2019 /PRNewswire/ --  Alkermes plc (Nasdaq:…

Alkermes +1.5% on tentative Vumerity approval

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Alkermes to Host Conference Call to Discuss Third Quarter 2019 Financial Results

DUBLIN , Oct. 16, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq:…

Alkermes Presents New Health Economics and Outcomes Research on Patients With Schizophrenia and Bipolar I Disorder at 2019 Psych Congress

DUBLIN , Oct. 7, 2019 /PRNewswire/ --   Alkermes…

Alkermes (ALKS) Investor Presentation - Slideshow

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Alkermes to Present at the Cantor Fitzgerald Global Healthcare Conference

DUBLIN , Sept. 26, 2019 /PRNewswire/ --  …

Alkermes Announces the Appointment of Richard Gaynor, M.D. and Andy Wilson to its Board of Directors and the Retirement of Director Floyd Bloom, M.D.

DUBLIN , Sept. 13, 2019 /PRNewswire/ --   Alkermes…

Alkermes (ALKS) Investor Presentation - Slideshow

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Alkermes upgraded to equal weight at Morgan Stanley

Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…

Alkermes: Offering A Speculative Entry Point

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis

DUBLIN and CAMBRIDGE, Mass. , July 30, 2019 /PRNewswire/ -- …

Alkermes Announces Settlement With Amneal Over VIVITROL® Patent Dispute

DUBLIN , July 29, 2019 /PRNewswire/ --  …

Alkermes Bounces Back -- but Not Enough

A slow launch has investors worried....…

Alkermes (ALKS) Earnings and Sales Beat Estimates in Q2

Alkermes (ALKS) surpasses earnings and sales estimates in the second quarter of 2019....…

Alkermes PLC (ALKS) Q2 2019 Earnings Call Transcript

ALKS earnings call for the period ending June 30, 2019....…

Alkermes plc (ALKS) CEO Richard Pops on Q2 2019 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Alkermes plc 2019 Q2 - Results - Earnings Call Slides

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…